Dolutegravir–rilpivirine for virological suppression
Abstract
One of the remaining issues in HIV therapeutics is whether, in the era of potent integrase inhibitors with a high genetic barrier to resistance, one or two companion drugs is needed for durable efficacy. Thus, the 48-week results of the SWORD-1 and SWORD-2 trials were big news in HIV treatment. 1 Llibre JM Hung C-C Brinson C et al. Efficacy, safety, and tolerability of dolutegravir–rilpivirine for the maintenance of virological suppression in...
Paper Details
Title
Dolutegravir–rilpivirine for virological suppression
Published Date
Sep 1, 2019
Journal
Volume
6
Issue
9
Pages
e560 - e561
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History